In high-risk patients with pulmonary arterial hypertension, Merck ’s fusion protein therapeutic Winrevair reduced the ...

Merck (NYSE:MRK) recently presented promising results from the Phase 3 ZENITH trial for its drug WINREVAIR, but the company's stock performance over the past month tells a different story, declining ...

Adding sotatercept (Winrevair) to the treatment regimen for pulmonary arterial hypertension (PAH) in high-risk patients ...

Merck (NYSE: MRK) is a top healthcare company with one of the best drugs ever made in its portfolio: Keytruda. During the ...

Merck dazzled with Phase 3 trial results for its PAH drug WINREVAIR, but the market responded with a collective shrug, ...

Merck is hoping that a new subcutaneous version of the drug (it's currently administered ... approved last year as a treatment for pulmonary arterial hypertension. Analysts believe that it may ...

which scientists think could lead to a partial reversal of the disease process in PAH. MSD – known as Merck & Co in the US and Canada – has predicted sales of the drug could reach upwards of $ ...

MSD's pulmonary arterial hypertension (PAH) drug Winrevair has been accelerating ... The company – known as Merck & Co in the US and Canada – acquired sotatercept as part of its $11.5 billion ...

Merck has a pipeline of scores of potential drugs in late-stage development. Andersen singled out Winrevair for pulmonary arterial hypertension, zilovertamab vedotin for cancer, and enlicitide ...

Eli Lilly and Company, AbbVie, Merck & Co., Inc., Pfizer, D-Wave Quantum, Johnson & Johnson, and Amgen are the seven ...